Huang Shuai-Wen, Long Hong, Huang Jia-Quan
Department of General Practice, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China.
Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China.
Pathogens. 2024 Dec 27;14(1):8. doi: 10.3390/pathogens14010008.
Due to the lack of agents that directly target covalently closed circular DNA and integrated HBV DNA in hepatocytes, achieving a complete cure for chronic hepatitis B (CHB) remains challenging. The latest guidelines recommend (hepatitis B surface antigen) HBsAg loss as the ideal treatment target for improving liver function, histopathology, and long-term prognosis. However, even after HBsAg loss, hepatitis B virus can persist, with a risk of recurrence, reactivation, cirrhosis, and hepatocellular carcinoma. Therefore, follow-up and surveillance are still necessary. With increasing treatment options available for achieving HBsAg loss in patients with CHB, developing effective surveillance strategies has become crucial. Recent studies on outcomes following HBsAg loss provide new insights for refining current surveillance strategies, though further improvement is needed through long-term observation and follow-up.
由于缺乏直接靶向肝细胞中共价闭合环状DNA和整合型乙肝病毒DNA的药物，实现慢性乙型肝炎（CHB）的完全治愈仍然具有挑战性。最新指南推荐乙肝表面抗原（HBsAg）消失作为改善肝功能、组织病理学和长期预后的理想治疗目标。然而，即使HBsAg消失后，乙肝病毒仍可能持续存在，存在复发、再激活、肝硬化和肝细胞癌的风险。因此，随访和监测仍然是必要的。随着CHB患者实现HBsAg消失的治疗选择不断增加，制定有效的监测策略变得至关重要。近期关于HBsAg消失后结局的研究为完善当前监测策略提供了新见解，不过仍需通过长期观察和随访进一步改进。
